Protocol Ledger

NCT07819435 · Phase II/III · RECRUITING

Phase 2/3 Efficacy and Safety of PP405 in Adult Males

Interventional Phase II/III clinical trial protocol NCT07819435 sponsored by Pelage Pharmaceuticals in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-09-21 Enrollment: 600 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07819435
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)600 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07819435
Protocol FieldVerified Registry Value
NCT IdentifierNCT07819435
Consolidated Lead SponsorPelage Pharmaceuticals
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment600 participants (ESTIMATED)
Registered Start Date2026-09-21
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI